pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
341
stories
14d
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
14d
STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work
stat
14d
Are healthcare systems really ready for GLP-1s?
biopharma dive
14d
Why is trust in science important?
stat
17d
STAT+: In a fight over denied claims, HCA sues out-of-state Blue Cross Blue Shield plan
stat
17d
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
18d
Definium’s new psychedelics data, and a reprieve for international scientists
stat
18d
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
19d
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
19d
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
fiercebiotech
19d
STAT+: House Democrats may use oversight powers to plan for health care overhaul
stat
20d
FDA clears first generic radioligand drug; Sionna turns to layoffs
biopharma dive
20d
STAT+: RFK Jr. returns to his roots
stat
20d
STAT+: FDA takes applications for new program to shorten drug approval times
stat
20d
STAT+: Medicare’s AI prior authorization pilot was rushed and full of problems, new documents reveal
stat
20d
Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
fiercebiotech
21d
Abbott agrees to settlement over closure of largest baby formula plant in the U.S.
stat
21d
STAT+: How $500 explains Republican health policy, and the GLP-1 Rx wave
stat
21d
Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand
biospace
21d
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
21d
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
fiercebiotech
21d
STAT+: What’s in a name? Novo looks to a rebrand
stat
21d
Cyclic peptides open new drug frontiers, if manufacturing can keep up
biospace
24d
Samsung Biologics inks $262M manufacturing deal with European pharma company
biospace
25d
Scientists boycott American Diabetes Association as fallout of June conference fracas escalates
fiercebiotech
25d
Why two promising heart drugs flopped and what’s next
stat
26d
Kura spins diabetes work into a Lilly-backed biotech startup
biopharma dive
26d
Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets
biospace
26d
Telemedicine company offers GLP-1s for addiction
stat
27d
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharma dive
← prev
page 3 of 12
next →
